MapLight Completes Enrollment in Schizophrenia Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 01 2026
0mins
Should l Buy MPLT?
Source: NASDAQ.COM
- Trial Enrollment Completed: MapLight Therapeutics has completed enrollment of 307 schizophrenia patients in its Phase 2 ZEPHYR trial, marking a significant milestone as the company advances mid-stage programs, with topline results expected by mid-August 2026, potentially impacting future growth positively.
- IRIS Trial Progress: Concurrently, the IRIS trial has also enrolled 161 participants with autism spectrum disorder, including over 100 adolescents, with the primary endpoint assessing changes in social communication skills over 12 weeks, demonstrating the company's ongoing commitment to CNS disorders.
- Strong Market Demand: CEO Chris Kroeger highlighted that robust enrollment reflects the significant unmet needs in central nervous system disorders, indicating the strategic importance of the company's research and development efforts in this area.
- Stock Performance: MPLT's stock has traded between $12.24 and $33.28 over the past year, closing at $31.87 on Thursday with a 5.22% increase, suggesting positive market expectations regarding the company's future potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MPLT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MPLT
Wall Street analysts forecast MPLT stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 29.200
Low
28.00
Averages
31.00
High
34.00
Current: 29.200
Low
28.00
Averages
31.00
High
34.00
About MPLT
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients suffering from debilitating central nervous system disorders (CNS). Its lead product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist, ML-007, co-formulated with a peripherally acting anticholinergic (PAC), which it is initially developing for the treatment of schizophrenia and Alzheimer’s disease psychosis (ADP). ML-007C-MA is designed to activate both M1 and M4 muscarinic receptors in the CNS to drive efficacy, while synchronizing the pharmacokinetics of the agonist and antagonist components to mitigate peripheral cholinergic side effects. Its second product candidate, ML-004, is a 5-HT1B/1D agonist that the Company is developing for the treatment of social communication deficit and/or irritability in autism spectrum disorder. It is also advancing two preclinical programs, ML-021 and ML-009.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MapLight Therapeutics Executive Sells Shares
- Executive Stock Sale: Jonathan Gillis, Chief Administrative Officer of MapLight Therapeutics, disclosed the direct sale of 69,835 shares of common stock on April 27 and 28, 2026, totaling approximately $2.09 million, indicating a strategic liquidity management approach.
- Transaction Plan Context: This sale was executed under a Rule 10b5-1 trading plan established on December 26, 2025, suggesting that it was a pre-scheduled routine transaction rather than an impulsive sell-off, thereby mitigating insider trading concerns.
- Shareholding Changes: Post-transaction, Gillis retains 181,219 shares of common stock, valued at around $5.49 million, reflecting his continued confidence in the company's future prospects.
- Market Reaction and Analysis: Although Gillis's sale contributed to an 8.63% drop in stock price, analysts remain optimistic about MapLight's potential, citing its innovative focus on central nervous system therapeutics as a significant market opportunity.
See More
MapLight Completes Enrollment in Schizophrenia Trial
- Trial Enrollment Completed: MapLight Therapeutics has completed enrollment of 307 schizophrenia patients in its Phase 2 ZEPHYR trial, marking a significant milestone as the company advances mid-stage programs, with topline results expected by mid-August 2026, potentially impacting future growth positively.
- IRIS Trial Progress: Concurrently, the IRIS trial has also enrolled 161 participants with autism spectrum disorder, including over 100 adolescents, with the primary endpoint assessing changes in social communication skills over 12 weeks, demonstrating the company's ongoing commitment to CNS disorders.
- Strong Market Demand: CEO Chris Kroeger highlighted that robust enrollment reflects the significant unmet needs in central nervous system disorders, indicating the strategic importance of the company's research and development efforts in this area.
- Stock Performance: MPLT's stock has traded between $12.24 and $33.28 over the past year, closing at $31.87 on Thursday with a 5.22% increase, suggesting positive market expectations regarding the company's future potential.
See More
Analysis of MapLight Therapeutics' Cash Burn
- Cash Reserve Status: As of December 2025, MapLight Therapeutics holds $305 million in cash and is debt-free, providing a cash runway of approximately 2.2 years, despite an annual cash burn of $139 million, indicating the company's ability to manage funds in its early stage.
- Cash Burn Increase: Over the past year, MapLight's cash burn has surged by 74%, which may suggest accelerated business development; however, this also means a faster depletion of cash reserves, potentially impacting future fundraising capabilities.
- Market Capitalization and Fundraising Ability: With a market capitalization of $1.3 billion, MapLight's cash burn accounted for 11% of its market value last year, indicating a strong capacity to raise funds through share issuance in the coming year, albeit at the cost of shareholder dilution.
- Risk Assessment: While MapLight's cash reserve situation is reassuring, the increasing cash burn rate raises concerns about the company's future growth, prompting investors to monitor potential risk signals to make informed investment decisions.
See More
MapLight Therapeutics Executive Sells Shares Amid Routine Liquidity Management
- Executive Stock Sale: Anatol Kreitzer, the Chief Discovery Officer of MapLight Therapeutics, sold 3,316 shares of common stock for approximately $88,000, reflecting a routine liquidity management strategy rather than a shift in conviction.
- Minimal Ownership Change: The sale constituted just 1% of Kreitzer's direct holdings, leaving him with 256,612 shares valued at about $6.9 million post-transaction, indicating sustained confidence in the company's prospects.
- Financial Overview: MapLight ended 2025 with $453.1 million in cash, sufficient to fund operations through 2027, despite R&D spending projected to rise to $138.3 million and quarterly net losses widening to $79.5 million.
- Clinical Trial Outlook: The company expects to complete Phase 2 enrollment for its lead schizophrenia program this month, with topline data due in Q3, and the clustering of multiple trial results could serve as significant valuation catalysts.
See More
Biotech Stocks Reach New 52-Week Highs
- Relay Therapeutics Progress: Relay Therapeutics' drug candidate Zovegalisib showed promising results in clinical trials, with a 7.64% stock price increase to $14.64 on Wednesday, indicating the company's potential in treating HR+/HER2- breast cancer, with initial data expected in the first half of 2026.
- MapLight Therapeutics High: MapLight Therapeutics' stock reached $25.79 during trading yesterday, up from its IPO price of $17.00, reflecting market optimism for its drug ML-007C-MA targeting schizophrenia and Alzheimer's disease, with trial results anticipated in Q3 2026.
- Oruka Therapeutics Development: Oruka Therapeutics' ORKA-001 and ORKA-002 are in clinical trials for psoriasis, with the stock hitting $64.61, showcasing market confidence in its drugs, and significant data expected in Q2 2026.
- Spyre Therapeutics Clinical Trials: Spyre Therapeutics' stock reached $54.33 yesterday, reflecting market interest in its investigational therapies, particularly the SKYLINE trial for active ulcerative colitis, with preliminary data expected in Q3 2026.
See More
MapLight Reports 2025 Financial Results and Clinical Milestones
- Increased Financial Losses: MapLight Therapeutics reported a net loss of $79.5 million for Q4 2025, significantly up from $21.2 million in the same period last year, with a total annual net loss of $161.2 million compared to $77.6 million in 2024, indicating ongoing pressure from R&D investments.
- Clinical Trial Progress: The company is advancing its ML-007C-MA drug in the ZEPHYR trial for schizophrenia, with enrollment expected to complete in April 2026 and topline results planned for Q3 2026, marking a critical milestone for future development.
- Multiple Drug Developments: MapLight is also progressing with ML-004 for autism spectrum disorder in the IRIS trial, which has completed enrollment, with topline data expected in Q3 2026, while candidate nomination for ML-055 is anticipated in 2026, showcasing the company's active pipeline across multiple R&D fronts.
- Strong Cash Position: As of 2025, MapLight holds $453.1 million in cash and investments, which is expected to fund operations through 2027, providing a financial cushion despite the losses and ensuring continued support for its R&D efforts.
See More
MapLight Therapeutics Executive Sells Shares
- Executive Stock Sale: Jonathan Gillis, Chief Administrative Officer of MapLight Therapeutics, disclosed the direct sale of 69,835 shares of common stock on April 27 and 28, 2026, totaling approximately $2.09 million, indicating a strategic liquidity management approach.
- Transaction Plan Context: This sale was executed under a Rule 10b5-1 trading plan established on December 26, 2025, suggesting that it was a pre-scheduled routine transaction rather than an impulsive sell-off, thereby mitigating insider trading concerns.
- Shareholding Changes: Post-transaction, Gillis retains 181,219 shares of common stock, valued at around $5.49 million, reflecting his continued confidence in the company's future prospects.
- Market Reaction and Analysis: Although Gillis's sale contributed to an 8.63% drop in stock price, analysts remain optimistic about MapLight's potential, citing its innovative focus on central nervous system therapeutics as a significant market opportunity.
See More
MapLight Completes Enrollment in Schizophrenia Trial
- Trial Enrollment Completed: MapLight Therapeutics has completed enrollment of 307 schizophrenia patients in its Phase 2 ZEPHYR trial, marking a significant milestone as the company advances mid-stage programs, with topline results expected by mid-August 2026, potentially impacting future growth positively.
- IRIS Trial Progress: Concurrently, the IRIS trial has also enrolled 161 participants with autism spectrum disorder, including over 100 adolescents, with the primary endpoint assessing changes in social communication skills over 12 weeks, demonstrating the company's ongoing commitment to CNS disorders.
- Strong Market Demand: CEO Chris Kroeger highlighted that robust enrollment reflects the significant unmet needs in central nervous system disorders, indicating the strategic importance of the company's research and development efforts in this area.
- Stock Performance: MPLT's stock has traded between $12.24 and $33.28 over the past year, closing at $31.87 on Thursday with a 5.22% increase, suggesting positive market expectations regarding the company's future potential.
See More
Analysis of MapLight Therapeutics' Cash Burn
- Cash Reserve Status: As of December 2025, MapLight Therapeutics holds $305 million in cash and is debt-free, providing a cash runway of approximately 2.2 years, despite an annual cash burn of $139 million, indicating the company's ability to manage funds in its early stage.
- Cash Burn Increase: Over the past year, MapLight's cash burn has surged by 74%, which may suggest accelerated business development; however, this also means a faster depletion of cash reserves, potentially impacting future fundraising capabilities.
- Market Capitalization and Fundraising Ability: With a market capitalization of $1.3 billion, MapLight's cash burn accounted for 11% of its market value last year, indicating a strong capacity to raise funds through share issuance in the coming year, albeit at the cost of shareholder dilution.
- Risk Assessment: While MapLight's cash reserve situation is reassuring, the increasing cash burn rate raises concerns about the company's future growth, prompting investors to monitor potential risk signals to make informed investment decisions.
See More
MapLight Therapeutics Executive Sells Shares Amid Routine Liquidity Management
- Executive Stock Sale: Anatol Kreitzer, the Chief Discovery Officer of MapLight Therapeutics, sold 3,316 shares of common stock for approximately $88,000, reflecting a routine liquidity management strategy rather than a shift in conviction.
- Minimal Ownership Change: The sale constituted just 1% of Kreitzer's direct holdings, leaving him with 256,612 shares valued at about $6.9 million post-transaction, indicating sustained confidence in the company's prospects.
- Financial Overview: MapLight ended 2025 with $453.1 million in cash, sufficient to fund operations through 2027, despite R&D spending projected to rise to $138.3 million and quarterly net losses widening to $79.5 million.
- Clinical Trial Outlook: The company expects to complete Phase 2 enrollment for its lead schizophrenia program this month, with topline data due in Q3, and the clustering of multiple trial results could serve as significant valuation catalysts.
See More
Biotech Stocks Reach New 52-Week Highs
- Relay Therapeutics Progress: Relay Therapeutics' drug candidate Zovegalisib showed promising results in clinical trials, with a 7.64% stock price increase to $14.64 on Wednesday, indicating the company's potential in treating HR+/HER2- breast cancer, with initial data expected in the first half of 2026.
- MapLight Therapeutics High: MapLight Therapeutics' stock reached $25.79 during trading yesterday, up from its IPO price of $17.00, reflecting market optimism for its drug ML-007C-MA targeting schizophrenia and Alzheimer's disease, with trial results anticipated in Q3 2026.
- Oruka Therapeutics Development: Oruka Therapeutics' ORKA-001 and ORKA-002 are in clinical trials for psoriasis, with the stock hitting $64.61, showcasing market confidence in its drugs, and significant data expected in Q2 2026.
- Spyre Therapeutics Clinical Trials: Spyre Therapeutics' stock reached $54.33 yesterday, reflecting market interest in its investigational therapies, particularly the SKYLINE trial for active ulcerative colitis, with preliminary data expected in Q3 2026.
See More
MapLight Reports 2025 Financial Results and Clinical Milestones
- Increased Financial Losses: MapLight Therapeutics reported a net loss of $79.5 million for Q4 2025, significantly up from $21.2 million in the same period last year, with a total annual net loss of $161.2 million compared to $77.6 million in 2024, indicating ongoing pressure from R&D investments.
- Clinical Trial Progress: The company is advancing its ML-007C-MA drug in the ZEPHYR trial for schizophrenia, with enrollment expected to complete in April 2026 and topline results planned for Q3 2026, marking a critical milestone for future development.
- Multiple Drug Developments: MapLight is also progressing with ML-004 for autism spectrum disorder in the IRIS trial, which has completed enrollment, with topline data expected in Q3 2026, while candidate nomination for ML-055 is anticipated in 2026, showcasing the company's active pipeline across multiple R&D fronts.
- Strong Cash Position: As of 2025, MapLight holds $453.1 million in cash and investments, which is expected to fund operations through 2027, providing a financial cushion despite the losses and ensuring continued support for its R&D efforts.
See More
